Pharmicell Co Ltd
Company Profile
Business description
Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.
Contact
12F Chungho B/D
3-2 Nonhyun-dong Gangnam-gu
Seoul135-010
KORT: +82 234960114
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
134
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,741.90 | 26.70 | -0.30% |
CAC 40 | 7,804.87 | 14.60 | 0.19% |
DAX 40 | 24,304.46 | 19.12 | -0.08% |
Dow JONES (US) | 42,762.87 | 443.13 | 1.05% |
FTSE 100 | 8,837.91 | 26.87 | 0.30% |
HKSE | 23,792.54 | 114.43 | -0.48% |
NASDAQ | 19,529.95 | 231.51 | 1.20% |
Nikkei 225 | 37,741.61 | 187.12 | 0.50% |
NZX 50 Index | 12,563.48 | 13.67 | -0.11% |
S&P 500 | 6,000.36 | 61.06 | 1.03% |
S&P/ASX 200 | 8,515.70 | 23.20 | -0.27% |
SSE Composite Index | 3,385.36 | 1.26 | 0.04% |